We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Sumitomo Dainippon

News List

Sumitomo Dainippon publishes positive results of schizophrenia drug pharmaceutical-technology
July 23, 2019
Japanese pharma company Sumitomo Dainippon has announced its drug Lonasen (blonanserin) has achieved its primary endpoint in a Phase III trial of 150 adolescents with schizophrenia.
Poxel, Sumitomo Dainippon's experimental type 2 diabetes drug imeglimin meets main goal of Phase III study firstwordpharma
April 10, 2019
Poxel and Sumitomo Dainippon Pharma on Tuesday announced that the investigational type 2 diabetes treatment……
Sumitomo Dainippon announces good results from trial of its lead drug pharmaceutical-technology
January 14, 2019
Japan-based Sumitomo Dainippon Pharma has published positive results from the phase III JEWEL trial into its drug Latuda (lurasidone hydrochloride) for patients with schizophrenia.....